2017 Cancer Annual Report

2017 Fremont Health Cancer Program Practice Profile Report (CP3R)

Caring for patients with breast cancer can be challenging for a very good reason. Breast cancer treatment is one of the most rapidly evolving fields in all of medicine.  For this reason collaboration with multiple specialties and tracking data is of the utmost importance if a healthcare facility strives to present patients with the most up to date options.  Unfortunately breast cancer is a very common diagnosis, affecting one in every eight women during their lifetime.  In order to maintain this high level of care Fremont Health has chosen to continually go through the rigorous process of a being a certified cancer program through the American College of Surgeon’s Commission on Cancer. 

In order to maintain this status Fremont Health must comply with a series of standards that have been set forth. One of these standards requires that the cancer program make public the results of their cancer care.  Also, it is required that cancer programs track their patients as they move the process of diagnosis, treatment and even long term follow up.  All of this work results in huge benefits to the program and to the individual patients.  One of these benefits is the ability to track your programs outcomes and compare them to similar programs across the country. 

One of these tracking programs is the Cancer Program Practice Profile Report (CP3R).  CP3R monitors a program’s level of compliance with certain parameters for each of ten different cancer sites.  The highest level that any particular parameter can reach is an Accountability Measure.  When a parameter becomes an Accountability Measure, it means that it is widely agreed upon based on the highest level of scientific data including multiple randomized controlled trials.  There are currently four such Accountability Measures for breast cancer.  These Accountability Measures are:

  • Radiation is administered within one year of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer
  • Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year of diagnosis for women with AJCC T1c or stage Ib-III hormone receptor positive breast cancer
  • Radiation therapy is recommended or administered following any mastectomy within 1 year of diagnosis of breast cancer for women with greater than or equal to 4 positive regional lymph nodes
  • Combination chemotherapy is recommended or administered within 4 months of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer

The Commission on Cancer has set the standard for the first three measures as greater than 90%. There is not currently a standard set for the fourth measure, however, it does allow the program to track their own outcomes.  We are currently able to see data dating back to 2011 and as recent as 2014.  During that four year period Fremont Health was 100% compliant with all four measures.  This confirms that, here at Fremont Health, our cancer program is providing our patients with the most up to date, scientifically proven breast cancer treatment. 

It is imperative of physicians and other healthcare providers to provide their patients with the best possible treatment strategies. In order to do so physicians and programs must frequently record and analyze their outcomes and to compare themselves to accepted benchmarks.  By obtaining and maintaining membership in the American College of Surgeon’s Commission on Cancer, Fremont Health has demonstrated its commitment to providing its patients with the highest level of cancer care.